Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced that it has added two more patents to its growing patent portfolio. The first patent, European Patent No. 1804831, expands the composition of matter claims covering HER-2 tumor antigens. The second patent, U.S. Patent No. 9,226,958, expands the use of the Company’s Lm Technology™ beyond oncology, specifically to induce an immune response in parasitically infected patients.

“These patents broaden our protection in HER2 and expand our reach beyond oncology, into parasitically infected patients,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “We are continuing to work diligently on our patent portfolio, currently with 90 granted patents and 111 pending applications, worldwide.”

Advaxis is the exclusive licensee of both of these patents. European Patent No. 1804831 will expire on September 14, 2025 and U.S. Patent 9,226,958 will expire on October 3, 2031. The company has an extensive patent portfolio that protects its product candidates and Listeria monocytogenes (Lm) based immunotherapy technology. The Company currently owns or has rights to more than 200 patents and applications globally, which are owned, licensed from, or co-owned with the Trustees of the University of Pennsylvania, Merck, Sharpe & Dohme BV, the National Institutes of Health, the University of Georgia Research Foundation, Inc., and Georgia Regents University. Its patents currently extend protection through 2032. (Original Source)

Shares of Advaxis Inc closed last Friday at $7.27 . ADXS has a 1-year high of $30.13 and a 1-year low of $6.60. The stock’s 50-day moving average is $10.26 and its 200-day moving average is $13.30.

On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on December 17, Janney Montgomery Scott analyst Roy Buchanan assigned a Buy rating on ADXS, with a price target of $22, which implies an upside of 202.6% from current levels. Separately, on December 15, H.C. Wainwright’s Swayampakula Ramakanth reiterated a Buy rating on the stock and has a price target of $30.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Roy Buchanan and Swayampakula Ramakanth have a total average return of -20.4% and -30.6% respectively. Buchanan has a success rate of 11.1% and is ranked #3219 out of 3582 analysts, while Ramakanth has a success rate of 10.0% and is ranked #3559.

Advaxis Inc is a clinical development stage biotechnology company. The Company is engaged in discovery, development and commercialization of Lm-LLO immunotherapies for cancer and infectious diseases.